


09-14-04

IPW



DOCKET NO.: ISIS-5300

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Brenda F. Baker, et al.

Confirmation No.: 7033

Application No.: 10/701,265

Group Art Unit: 1635

Filing Date: November 4, 2003

Examiner: Not Yet Assigned

For: CHIMERIC OLIGOMERIC COMPOUNDS AND THEIR USE IN GENE MODULATION

EXPRESS MAIL LABEL NO: EL999284058US

DATE OF DEPOSIT: September 13, 2004

EL 999284058US

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:
 - Certification in Accordance with § 1.97(e) is attached; or
 - The fee of \$180.00 as set forth in § 1.17(p) is attached.
- In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).
- Copies of reference numbers 234-240 listed on the attached Form PTO-1449 are enclosed herewith.
- A copy of reference number 241 on the attached Form PTO 1449 is not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).
- Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.
- The relevance of those listed references which are not in the English language is as follows:

Enclosed is a copy of the PCT International Search Report dated August 23, 2004 (number 234 on Form PTO-1449), which indicates the references considered to be relevant.

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: September 13, 2004

John A. Harrelson, Jr.
John A. Harrelson, Jr.
Registration No. 42,637

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2004 WW



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ISIS-5300	Application No. 10/701,265
	Applicant Brenda F. Baker, et al.	
	Filing Date November 4, 2003	Group 1635
	Confirmation No. 7033	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

234	Copy of the PCT International Search Report dated August 23, 2004 (PCT/US03/35063)
235	Beigelman, L., et al., "Chemical modification of hammerhead ribozymes," <i>J. of Biological Chem.</i> , 1995, 270(43), 257082-25708
236	Caplen, N.J., et al., "Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems," <i>PNAS</i> , 2001, 98(17), 9742-9747
237	Czauderna, F., et al., "Structural variations and stabilizing modifications of synthetic siRNAs in mammalian cells," <i>Nucleic Acids Res.</i> , 2003, 31(11), 2705-2716
238	Paddison, P.J., et al., "Stable suppression of gene expression by RNAi in mammalian cells," <i>PNAS</i> , 2002, 99(3), 1443-1448
239	Sui, G., et al., "A DNA vector-based RNAi technology to suppress gene expression in mammalian cells," <i>PNAS</i> , 2002, 99(8), 5515-5520
240	Yu, J.-Y., et al., "RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells," <i>PNAS</i> , 2002, 99(9), 6047-6052

EXAMINER	DATE CONSIDERED
-----------------	------------------------

Form PTO-1449 Modified	Docket No. ISIS-5300	Application No. 10/701,265
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)	Applicant Brenda F. Baker, et al.	
U.S. Department of Commerce Patent and Trademark Office	Filing Date November 4, 2003	Group 1635
	Confirmation No. 7033	-

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

EXAMINER

DATE CONSIDERED